Epigenomics AG / Key word(s): Study/Study results 08.05.2015 09:04 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Epigenomics Reaches 99.5 % Adherence for Epi proColon(R) in ADMIT Study Berlin, Germany, May 8, 2015 - Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) announces results from the ADMIT trial (ADherence to Minimally Invasive Testing - NCT02251782) for its non-invasive blood-based test for colorectal cancer (CRC) screening, Epi proColon(R). The study demonstrated a 99.5% rate of adherence to CRC screening using Epi proColon(R), while the fecal immunochemical test (FIT) showed an adherence rate of 88.1%. These numbers contrast to a baseline adherence to standard of care CRC screening of less than 25%, as measured in a passive control arm in which previously non-compliant patients were offered CRC screening tests (FIT or colonoscopy) as part of their standard of care. Adherence to Epi proColon(R) was significantly greater than adherence to FIT, with an observed difference of 11.4% (p< 0.0001). The study was designed to determine whether the adherence to Epi proColon(R) was significantly greater than to FIT plus a margin of 8.2%. This margin was determined before the study based on a projected FIT adherence rate. While adherence to Epi proColon(R) ultimately was higher than the FIT adherence plus 8.2%, the comparison fell just short of statistical significance (p=0.059). However, given the difference in the observed FIT adherence rate in the study from the projected one, demonstrating an adherence to Epi proColon(R) equaling the FIT adherence rate plus a margin of 3.2% would have been sufficient to prove superiority. In this scenario, the observed difference in adherence (11.4%) met statistical significance (p< 0.0001). Seeing adherence with Epi proColon approaching 100% clearly confirms Epigenomics' assumption that blood-based CRC screening has the potential to significantly lower the barrier for patients that have been historically non-compliant to participate in CRC screening programs. The Company is convinced that the study results support its pre-market approval (PMA) application for Epi proColon(R) and plans to submit the data and further discuss the study results with the U.S. Food and Drug Administration (FDA) over the next few weeks. The ADMIT trial was requested by the FDA in the context of Epigenomics' PMA application for Epi proColon(R). The study was originally designed to investigate CRC screening participation for average risk, screening eligible study subjects that were historically non-compliant to offered guideline-recommended screening methods (colonoscopy or FIT testing) and included 413 eligible subjects identified by Epigenomics' clinical trial partners, Kaiser Permanente and Geisinger Health Systems. Study subjects were randomized to either a FIT test kit for home use or a blood draw for the Epi proColon(R) test. Rates of adherence were compared between those that accepted and completed the blood test and those that accepted and completed the FIT test. An observational secondary objective of the study aims to demonstrate the number of patients who completed colonoscopy after positive test results with Epi proColon(R) or FIT. This data will be reported to the FDA once the study is formally completed within the next few weeks, i.e. up to six weeks after the last positive test result of a study subject was obtained. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Further Information For further information please refer to the press release issued today by Epigenomics AG at www.epigenomics.com. Conference call for press and analysts Epigenomics' management will host a conference call at 3pm CET/9 am ET today, Friday 8th May 2015. The dial-in numbers for the conference call are: Dial-in number (within Germany): +49 69 247 501 895 Dial-in number (within the UK): +44 203 367 92 16 Dial-in number (within the U.S.): +1 408 9169 838 Participants are kindly requested to dial in 10 minutes prior to the start of the call. An audio replay of the conference call will be provided on Epigenomics' website subsequently: http://www.epigenomics.com/en/news-investors.html Epigenomics' legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology, which may be sold at some future time in the U.S. have not been established. Contact: Epigenomics AG Antje Zeise CIRO Manager IR | PR Epigenomics AG Phone: +49 (0) 30 24345 386 ir@epigenomics.com www.epigenomics.com 08.05.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Epigenomics AG GeneststraÃe 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A11QW50 WKN: A11QW5 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Epigenomics Reaches 99.5 % Adherence for Epi
Top 10 Most Recent News Articles
Evotec’s $2.9M Grant Advances Drug Safety Tech
Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...
Continue Reading
Berry Street Integrates AI with What Matters: Human Touch
Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...
Continue Reading
Flagship's £100M London Move to Ignite AI Ventures
London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...
Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List
Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...
Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle
Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...
Continue Reading
Daqo New Energy Faces Key Investor Meeting in December
Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...
Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza
KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...
Continue Reading
ZTE Reinvents Energy for AI Data Centers
The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...
Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050
Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...
Continue ReadingSivers Semiconductors: Strategy Behind 2027 AGM Plans
Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...
Continue ReadingTop 5 Most Recently Viewed Articles
Cypherpunk Technologies Boosts Zcash Holdings Significantly Year-Over-Year
Cypherpunk Technologies Expands Zcash Accumulation CAMBRIDGE, Mass. — Cypherpunk Technologies Inc. (Nasdaq: CYPH), a company deeply engaged in privacy technology, has recently accelerated its efforts to accumulate Zcash, significantly boosting its treasury holdings. This move reflects their strategic commitment to enhancing their corporate asset portfolio and addressing...
Continue Reading
Insights from Access LIVE: The Future of Beverage Leadership
Insights from Access LIVE: The Future of Beverage Leadership Leaders from the nation's largest distributors convened to share their insights on innovation, growth, and the future of the beverage alcohol industry. The session, known as "Wholesaler Power Hour — Market Drivers: Wholesale Leaders Blazing a Path to Success," took place on the LIVE Stage at Access LIVE 2025,...
Continue Reading
Understanding Microsoft's Competitive Edge in the Software Sector
Dynamic Insights into Microsoft and Its Competitors In the rapidly evolving business landscape, a thorough examination of companies is vital for investors and enthusiasts alike. This article delves into a detailed comparative analysis of Microsoft (NASDAQ: MSFT) relative to its main competitors within the software industry. By evaluating essential financial metrics,...
Continue Reading
The Transformative Financial Journey of Pan American Silver Stock
The Impact of Long-Term Investment in Pan American Silver Investing in stocks is often seen as a journey, and Pan American Silver (NYSE: PAAS) stands as a shining example of how patience can yield extraordinary rewards over the years. Over the last decade, Pan American Silver has surpassed market performance, boasting an annualized return of 22.95%, which is significantly...
Continue Reading
Linc Housing Initiates Construction of 90 Affordable Units
Linc Housing Begins Construction on New Affordable Homes In a promising development for families in need, Linc Housing has commenced the construction of three new affordable apartment communities. This initiative will create 90 new homes specifically designed for low-income individuals and families. The timing could not be more critical, as communities grapple with an...
Continue Reading